Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.

about

Early tumor shrinkage as an "on-treatment" clinical predictor of long-term outcome in solid organ cancers.

P2860

Q42330726-49194546-34A6-40E3-90D1-764502057B00

P2860

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.

Item

http://www.wikidata.org/entity/Q42921489

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Interpreting overall survival ...... nal cell carcinoma case study.

@en

Interpreting overall survival ...... nal cell carcinoma case study.

@nl

type

Item

label

Interpreting overall survival ...... nal cell carcinoma case study.

@en

Interpreting overall survival ...... nal cell carcinoma case study.

@nl

prefLabel

Interpreting overall survival ...... nal cell carcinoma case study.

@en

Interpreting overall survival ...... nal cell carcinoma case study.

@nl

P1476

Interpreting overall survival ...... nal cell carcinoma case study.

@en

P2093

Connie Chen

http://www.w3.org/2001/XMLSchema#string

Linus Jönsson

http://www.w3.org/2001/XMLSchema#string

Orjan Akerborg

http://www.w3.org/2001/XMLSchema#string

Paul Bycott

http://www.w3.org/2001/XMLSchema#string

Sylvie Negrier

http://www.w3.org/2001/XMLSchema#string

Yiyun Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Detecting an overall survival benefit that is derived from progression-free survival

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies

Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-

P304

365-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S67249

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25278784

http://www.w3.org/2001/XMLSchema#string

P932

4179830

http://www.w3.org/2001/XMLSchema#string

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.

about

P2860

P2860

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932